Table 2

Adverse events by study group

0.03 mg

(N = 7)

0.1 mg

(N = 6)

0.3 mg

(N = 6)

1 mg

(N = 6)

Placebo

(N = 8)


Number of Patients with at least one AE

7 (100%)

5 (83.3%)

5 (83.3%)

6 (100%)

7 (87.5%)


Number of Patients with no AE

0 (0%)

1 (16.7%)

1 (16.7%)

0 (0%)

1 (12.5%)


Arthralagia

4 (57.1%)

1 (16.7%)

5 (83.3%)

5 (83.3%)

6 (75%)


Nasopharyngitis

2 (28.6%)

2 (33.3%)

1 (16.7%)

0 (0%)

1 (12.5%)


Upper Respiratory Tract Infection

1 (14.3%)

0 (0%)

3 (50%)

1 (16.7%)

1 (12.5%)


Headache

1 (14.3%)

2 (33.3%)

2 (33.3%)

0 (0%)

1 (12.5%)


Influenza

0 (0%)

2 (33.3%)

0 (0%)

0 (0%)

2 (25%)


Joint Stiffness

2 (28.6%)

1 (16.7%)

1 (16.7%)

0 (0%)

1 (12.5%)


Joint Swelling

2 (28.6%)

0 (0%)

0 (0%)

1 (16.7%)

0 (0%)


Lymphadenopathy

0 (0%)

1 (16.7%)

0 (0%)

1 (16.7%)

0 (0%)


Injection Site Bruising

0 (0%)

2 (33.3%)

0 (0%)

0 (0%)

0 (0%)


Injection Site Pain

1 (14.3%)

0 (0%)

0 (0%)

4 (66.7%)

1 (12.5%)


Injection Site Mass

0 (0%)

1 (16.7%)

0 (0%)

1 (16.7%)

0 (0%)


Injection Site Swelling

1 (14.3%)

0 (0%)

1 (16.7%)

1 (16.7%)

0 (0%)


Hunter et al. BMC Musculoskeletal Disorders 2010 11:232   doi:10.1186/1471-2474-11-232

Open Data